Summary Cisplatin resistance, induced in murine fibrosarcoma cells (SSK) in vitro or in vivo by low-dose irradiation, can be overcome by activation of the cyclic GMP(cGMP)-dependent transduction pathway. This is mediated either by stimulating cGMP formation with sodium nitroprusside or by replacing cGMP with a selective activator of the cGMP-dependent protein kinase, 8-bromo-cGMP. The cyclic AMP-dependent transduction pathway is not involved in cisplatin resistance. Instead, activation of cAMP sensitises both parental and resistant SSK cells equally to the action of cisplatin. There is a 1.8 to 2.5-fold increase in drug toxicity, depending on the activating agent. Enhancement of cisplatin sensitivity is induced by specific inhibition of cAMP hydrolysis, increase in cAMP formation or by increasing the activation potential to cAMP-dependent protein kinase by specific cAMP analogues. Cells that have lost cisplatin resistance respond to cGMP-or cAMP-elevating agents in the same way as the parental SSK cells. The radiation sensitivity is unchanged in all cell lines, even after activation of cAMP or cGMP. These results suggest that specific DNA repair pathways are altered by radiation but affected only in cisplatin damage repair, which is regulated by cGMP. Although there is ample cooperativity and interaction between the cAMP-and the cGMP-dependent transduction pathways, specific substrate binding by cGMP appears to play an important role in radiationinduced cisplatin resistance.
Recently, we reported that cisplatin resistance after low-dose irradiation is associated with alterations in the cAMPdependent signal transduction pathway in murine SSK fibrosarcoma cells (Eichholtz-Wirth and Hietel, 1994) . In the presence of the non-selective phosphodiesterase inhibitor 3-isobutyl-l-methylxanthine (IBMX), cisplatin sensitivity could be restored in the resistant SSK cells, whereas only little effect was observed in the parental SSK cells. This implies that cAMP or cGMP is the target in the cascade of signal transduction.
The two second messengers cAMP and cGMP are key regulatory molecules with specific cellular functions. Cyclic AMP mediates its effects through binding to its main receptor protein, cAMP-dependent protein kinase (cAMP-PK) which exists in different subunits with various isoforms (Ogreid et al., 1989; Cho-Chung, 1990 ). These isozymes differ in tissue distribution, cAMP dissociation rate and analogue specificity. They may be selectively modulated by autophosphorylation, by cross-activation with cGMP binding sites or by translocation (Jiang et al., 1992) . The cAMP-dependent protein kinase may activate transcription factors, which affect -by positive or negative regulation -DNA-binding activity, the transcriptional activity or the subcellular localisation of transcription factors. One of the best studied transcription factors is the cAMP response element-binding protein CREB (Karin, 1994) , which has also been associated with drug-resistance (Rohlff et al., 1993a) .
The cGMP is less widely abundant and distributed than cAMP, but also has a diversity of cellular effects. cAMP-PK and cGMP-PK are evolutionarily related enzymes which are homologous in structure and function and similar in substrate specificity (Francis and Corbin, 1994 ). There are three major receptor proteins in mammalian cells: the cGMP-gated cation channel, cGMP-stimulated and inhibited phosphodiesterase (PDE) and cGMP-dependent protein kinase, cGMP-PK (Hofmann et al., 1992) . These receptor proteins differ widely in specific cells and they may be positively or negatively affected by cGMP (Lincoln and Cornwell, 1993) . Autophosphorylation of type I cGMP-PK in the presence of cAMP increases basal activity and affinity for cAMP and decreases cooperativity between cGMP binding sites.
One of the major mechanisms of cGMP-PK-catalysed phosphorylation in most tissues is the regulation of intracellular Ca2" levels. The cGMP-dependent signal transduction cascade is not well understood and may involve phosphorylation of other cGMP receptors, such as the high mobility group protein (HMG), which has been associated with cisplatin resistance (Walton et al., 1982; Chao et al., 1991) . IBMX inhibits the hydrolysis of both the short-lived second messengers cAMP and cGMP.
To analyse further the mechanism of radiation-induced cisplatin resistance in our SKK cells, it therefore has to be determined whether the cAMP-dependent or the cGMPdependent signal transduction pathway is affected. Owing to ample cooperativity between these two pathways, it (Beavo and Reifsnyder, 1990 Abnormal expression of type I and type II cAMP-PK has been described with changes in cAMP receptor isoforms (Ogreid et al., 1989; Cho-Chung, 1990 Cell lines Induction of cisplatin resistance after low-dose radiation and cisplatin conditioning was described in detail recently (Eichholtz-Wirth and Hietel, 1994 Eichholtz and Hietel, 1994) , except for slightly longer doubling times (12-15 h as compared with 11 -13 h for SSK cells). Glutathione (GSH) content is not significantly different, while cadmium chloride sensitivity, which is an indirect measure of metallothioneins (Eichholtz-Wirth et al., 1993) , is reduced in SSK-R3 cells by a factor of 1.6.
Cell culture All cell lines were grown as monolayer cultures in Eagle's MEM, supplemented with 10% newborn calf serum, 0.01% bycomycin and 0.035% sodium bicarbonate and maintained at 37°C at pH 7.4 in a controlled carbon dioxide atmosphere (3-3.5% carbon dioxide).
Determination of drug and radiation sensitivity To establish cisplatin survival curves, exponentially growing cells were appropriately diluted and allowed to attach to the glass surface overnight. Exposure to cisplatin in combination with or without other drugs was carried out in culture medium at varying cisplatin concentrations. The drugs were freshly diluted in Hanks' solution and added to the culture medium. After the allotted exposure time the medium was decanted, the cells rinsed with Hanks' solution and fresh culture medium was added.
For combined treatment experiments, using cisplatin (or radiation) and a second drug, non-toxic or low-toxic drug concentrations were used for the second drug, resulting in a cell survival of 0.8-1.0 for the second drug alone; in any case, the surviving fractions were corrected for the toxicity of this second drug alone.
To generate radiation survival curves, cells were exposed to graded single doses of 7-rays from a Gammacell 40 caesium-137 source at a dose rate of 1.2 Gy min-'. For combined treatment, the cells were exposed to the drugs directly before irradiation. After 7-9 days' incubation, all flasks were scored for colonies of 50 or more cells. The surviving fraction (SF) was corrected for the plating efficiency of untreated cells. tively). There is also differential enhancement in c-isplatin toxicity when the cells are exposed in combination with the cGMP agonist 8-Br-cGMP (Figure 2b ; EF = 2.5 and 1.7 for SSK-R3 and SSK cells respectively).
Selective inhibition of the various PDE isoforms is presented in Table I . Amrinone is efficient against the cGMPinhibited PDE III. Propentofylline inhibits cAMP-specific PDE IV and, to a lesser extent, the calcium-calmodulindependent isoform I. Dipyridamole, the cGMP-specific inhibitor of type V PDE, is also a potent inhibitor of More widely used cyclic nucleotide substituents, which have been associated with drug resistance and inhibition of proliferation, also increase cisplatin sensitivity in both cell lines, but do not play any specific role in radiation-induced cisplatin resistance in SSK cells (Table II) . 8.Cl-cAMP enhances cisplatin sensitivity slightly more than 8-Br-cAMP, but there is no significant difference between the enhance- In contrast to the enhancement of cisplatin cytotoxicity by various agonists of the cAMP and cGMP-dependent pathways, cisplatin sensitivity is unchanged upon activation of the more prominent protein kinase C pathway. Neither the PKC activator TPA nor the PKC inhibitor staurosporine exerts any influence on SSK-R3 or SSK cell survival in combination with cisplatin ( Figure 3) .
As has already been seen in cisplatin-resistant SSK cells that were induced by high-dose irradiation (Eichholtz-Wirth et al., 1993) , the radiation sensitivity was again unchanged in SSK-R3 and SSK cells (Figure 4) . When the cells were irradiated immediately after 1 h SNP treatment as described for the corresponding cisplatin experiments, there was no alteration in radiosensitivity.
SSK-R5 cells which had been irradiated but not cisplatin conditioned as the SSK-R3 cells exhibited a short, transient cisplatin resistance only during 20-30 cell cycles. When they have lost their cisplatin resistance, these cells respond to cGMP agonists in a similar way as do the parental SSK cells ( Figure 5 ). There is no significant difference in the enhancement factors.
10°D iscussion
The present data demonstrate that radiation-induced cisplatin resistance in murine fibrosarcoma SSK-R3 cells can be overcome by stimulation of the cGMP-dependent transduction pathway. This activation may be achieved with similar effectiveness by enhancing cGMP formation with SNP or by increasing cGMP binding by replacing cGMP with the cGMP analogue 8-Br-cGMP.
This analogue was selected because of its higher specificity and lipophilicity as compared with cGMP; it is hydrolysed only to a small extent by cyclic nucleotide phosphodiesterases and it is a poor activator of the cAMP-dependent protein kinase . This cGMP agonist has a higher potency to activate cGMP-PK than cGMP (Ka for the regulatory subunit type Io = 4.3) with preferential binding to the slow exchanging site (Sekhar et al., 1992) .
SNP enhances cGMP by stimulation of guanylate cyclase; there are conflicting findings as to the activation of the cGMP-dependent kinase by SNP (Lincoln and Keely, 1981; Geiger et al., 1992) , which might be affected differently in various cell types.
Using these two cGMP-selective agents, it is possible to distinguish between the cAMP-dependent and the cGMP- dependent transduction pathways. Selective restoration of cisplatin sensitivity in the resistant SSK-R3 cells is observed only after stimulation of the cGMP-dependent pathway, and not after activation of the cAMP-dependent transduction pathway. This differential effect of cGMP-enhancing agents on sensitive and resistant SSK cells correlates with loss of drug resistance. In addition, the enhancement of cisplatin cytotoxicity is unlikely to be due to the expression of cell damage by free radicals, since the cGMP analogue 8-BrcGMP is structurally different from the nitric oxidegenerating drug SNP. The alteration in the cGMP pathway in SSK-R3 cells does not seem to be associated with enhanced hydrolysis of one of the phosphodiesterase isozymes, although the diversity of isozymes may reveal high variation in regulatory interactions. Moreover, cGMP exerts one of its main regulatory functions on the receptor protein phosphodiesterase (Lincoln and Cornwell, 1993) . In SSK and SSK-R3 cells, specific inhibition of the PDE isozymes increased cisplatin sensitivity in both cell lines, without differential effects on SSK-R3 cells. Mechanisms other than recognition of specific motifs may contribute to selective cGMP-mediated protein phosphorylation. Little is known about protein substrates for cGMP-PK and their localisation. One of the possible substrates may include the HMG proteins, which are specifically phosphorylated by cyclic nucleotide-dependent protein kinases (Walton et al., 1982) . These transcription factors regulate, at least in part, the relative sensitivity of cells to cisplatin. They recognise the distortions in DNA structure resulting from cisplatin-adduct formation, preferentially bind to cisplatindamaged DNA and allow increased accessibility of DNA repair enzymes (Chao et al., 1991; Hughes et al., 1992) . In cisplatin-resistant HeLa cells overexpression of damage recognition proteins has been suggested to be responsible for altered DNA repair and emergence of drug resistance (Chao et al., 1991) .
The recently described absence of cross-resistance towards other cytostatic drugs in resistant SSK cells (Eichholtz-Wirth and Hietel, 1994) would also argue for cisplatin-specific transcription factors to be involved in altered damage recognition and repair in SSK-R3 cells. This raises the possibility that these widely distributed chromatin proteins are substrates for cGMP or cGMP-PK in SSK-R3 cells.
In most reports on the involvement of signal transduction pathways in drug resistance, alterations of the more prominent protein kinase C pathway have been observed (Isonishi et al., 1990; Basu and Lazoa, 1992; Rubin et al., 1992 (Rohlff et al., 1993a) . Concurrently, there was a reduction in the DNA-binding activity of the transcription factors CREB, AP-1 and AP-2, whose activities were markedly enhanced in the resistant cells. In contrast to our results, drug cytotoxicity could be enhanced in cisplatinresistant human ovarian carcinoma cells 2008 by treatment with IBMX, but not with the adenyl cyclase agonist forskolin (Mann et at., 1991) . This cyclic nucleotide-dependent cisplatin response was later shown to be associated with alterations of microtubules (Christen et al., 1993 Hietel, 1994) .
The data suggest that, in SSK cells, the cAMP-dependent
Cisplatin resistance and cGMP-PK H Eichholtz-Wirth 291 transduction pathway is not associated with cisplatin resistance, but rather confers increased drug toxicity in both cell lines. This is demonstrated by combined treatment of cisplatin with cAMP analogues or with isoprenaline, which stimulates cAMP formation by activation of adenylate cyclase (Hall et al., 1992) . Of the various cAMP analogues described in the literature, we used 8-Br-cAMP, which has a lower activation constant for PKA and slightly greater lipophilicity than cAMP (Sandberg et al., 1991) and, because of its specificity, allows a distinction between the cAMP-and the cGMP-dependent transduction pathway. 8-cpt-cAMP, which has been extensively studied as a selective activator of cAMP-dependent protein kinase, is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase type V (Connolly et al., 1992) and stimulates both cGMP-PK-and cAMP-PKmediated protein phosphorylation (Sandberg et al., 1991) . 8-Cl-cAMP was reported by Cho-Chung (1990) to be an excellent site-selective cAMP analogue owing to high-affinity binding to RII but not RI and low activation constant for RII. This analogue, however, might act through its adenosine metabolite (van Lookeren Campagne et al., 1991; LangeCarter et al., 1993) . 8-Cl-cAMP and 8-cpt-cAMP are therefore not good choices as site-selective cAMP analogues when the effects of cGMP and cAMP are to be distinguished. The changes that account for the observed cisplatin resistance involve steps in the signal transduction pathway distinct from those that participate in the cAMP-dependent increase in cisplatin sensitivity. Although there is a close relationship between the cGMPdependent and the cAMP-dependent pathway, with ample cooperativity and interactions between these two pathways, our results suggest that a specific substrate is phosphorylated only by the cGMP-dependent pathway, which is a mediator of cisplatin resistance. The increase in cisplatin sensitivity after stimulation of the cAMP-dependent pathway which is seen in resistant and sensitive SSK cells may be related to activation of transcription factors, such as CREB or AP-1 or with altered expression of type I and type II cAMPdependent protein kinase, as described above.
Radiation rapidly activates early response gene signalling cascades (Wilson et al., 1993) , however altered response to ionising radiation has been reported only after inhibition of protein kinase C (Hallahan et al., 1992) , but not in relation to cyclic nucleotides. In SSK-R3 cells, the radiosensitivity is not significantly changed compared with the parental cells, with or without additional SNP treatment. A possible explanation is that cisplatin-specific DNA repair pathways are altered in the resistant cells. These changes are probably not involved in the damage repair after ionising radiation and are regulated by a cGMP-dependent pathway.
The present results demonstrate that radiation-induced cisplatin resistance in SSK-R3 cells can be overcome by stimulation of the cGMP-dependent transduction pathway. Enhancement of the closely related cAMP-dependent pathway does not correlate with cisplatin resistance; however, it markedly increases cisplatin cytotoxicity in sensitive and resistant SSK cells. It will be of interest now to determine the cGMP receptor in SSK-R3 cells and to see whether radiation-induced alterations of the cGMP-dependent transduction pathway are also observed in different cell systems.
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